A5017608818- Gout, Hyperuricemia, Uric Acid
- Urticaria and Related Conditions
- Case Reports on Hematomas
- Systemic Lupus Erythematosus Research
- Innovations in Medical Education
- Vasculitis and related conditions
- Primary Care and Health Outcomes
- Rheumatoid Arthritis Research and Therapies
- Health and Medical Research Impacts
- Clinical practice guidelines implementation
- Advances in Oncology and Radiotherapy
- Musculoskeletal Disorders and Rehabilitation
- Empathy and Medical Education
- Vaccine Coverage and Hesitancy
- Lipoproteins and Cardiovascular Health
- Health Systems, Economic Evaluations, Quality of Life
- Inflammatory mediators and NSAID effects
- Spondyloarthritis Studies and Treatments
- Health Sciences Research and Education
- Systemic Sclerosis and Related Diseases
- Hepatitis C virus research
- Venous Thromboembolism Diagnosis and Management
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Inflammatory Myopathies and Dermatomyositis
- Bone and Joint Diseases
Cleveland Clinic Lerner College of Medicine
2009-2024
Cleveland Clinic
2012-2023
Case Western Reserve University
2010-2023
The Sense Innovation and Research Center
2015
University of California, Los Angeles
2013
Virginia Commonwealth University Medical Center
2009
Johns Hopkins University
2009
Biogen (United States)
2009
Geisinger Medical Center
2009
University of Pennsylvania
1986-1990
Guidelines and recommendations
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns practice not dictate care a patient.The ACR considers adherence these guidelines be voluntary, with ultimate determination regarding their application made physician in light each patient's individual circumstances.Guidelines promote beneficial or desirable outcomes but cannot guarantee any specific outcome.Guidelines subject periodic...
Abstract Objective To evaluate treatment with methotrexate (MTX) in patients newly diagnosed giant cell arteritis (GCA) to determine if MTX reduces GCA relapses and cumulative corticosteroid (CS) requirements diminishes disease‐ treatment‐related morbidity. Methods This was a multicenter, randomized, double‐blind study. Over 4 years, 16 centers from the International Network for Study of Systemic Vasculitides enrolled unequivocal GCA. The initial 1 mg/kg/day (≤60 mg every day) prednisone,...
Glycoproteins having mannose and/or N-acetylglucosamine in the terminal non-reducing position [Stockert, Morell & Scheinberg (1976) Biochem. Biophys. Res. Commun. 68, 988–993], and various lysosomal enzymes [Stahl, Schlesinger, Rodman Doebber Nature (London) 264, 86–8] are rapidly cleared from plasma by liver after intravenous administration. A cell-separation technique was used to determine cellular localization of 125I-labelled beta-glucuronidase, ribonuclease B, agalacto-orosomucoid...
In patients with COVID-19, granulocyte-macrophage colony stimulating factor (GM-CSF) might be a mediator of the hyperactive inflammatory response associated respiratory failure and death. We aimed to evaluate whether mavrilimumab, monoclonal antibody GM-CSF receptor, would improve outcomes in COVID-19 pneumonia systemic hyperinflammation.This investigator-initiated, multicentre, double-blind, randomised trial was done at seven hospitals USA. Inclusion required hospitalisation, pneumonia,...
Purpose: To report a case of severe anterior uveitis flare following the administration etanercept (Enbrel) for ankylosing spondylitis and to review literature pertaining inflammatory eye disease associated with use etanercept. Methods: Clinical data were collected from 52-year-old female chronic symptomatic spondylitis. The relationship between patient's systemic ocular inflammation was assessed. A conducted identify additional reports. Results: patient history exhibited acute exacerbations...
Abstract A subcutaneous air pouch formed in Sprague‐Dawley rats was used to study the effect of diets enriched γ‐linolenic acid (GLA) (in plant seed oil) and eicosapentaenoic (EPA) fish on acute inflammation induced by monosodium urate crystals. The GLA‐enriched diet suppressed significantly cellular phase (polymorphonuclear leukocyte accumulation, crystal phagocytosis, lysosomal enzyme activity), but it had little fluid (exudate volume protein concentration). In contrast, EPA‐enriched not...
<b>Objective:</b> To assess the safety, tolerability, and efficacy of interferon beta-1a (IFNβ-1a) combined with methotrexate (MTX), IV methylprednisolone (IVMP), or both in patients relapsing-remitting multiple sclerosis (RRMS) continued disease activity on IFNβ-1a monotherapy. <b>Methods:</b> Eligibility criteria included RRMS, Expanded Disability Status Scale score 0–5.5, ≥1 relapse gadolinium-enhancing MRI lesion prior year Participants weekly 30 μg IM were randomized a 2 × factorial...
Phagocytosis of urate crystals by human or rabbit neutrophils induces the synthesis and release a glycoprotein, crystal-induced chemotactic factor (CCF), which is chemotactically active both in vitro vivo. It has been proposed that CCF prime mediator acute gouty attack. Colchicine shown to decrease production this vitro. In these studies, colchicine, at nonleukopenic doses, abrogate arthritis induced monosodium rabbits, but have no effect upon injection purified cell-derived factor. Serum...
A factor with chemotactic properties for neutrophils and mononuclear cells was extracted from the lysosomal fraction of both human rabbit that had been allowed to phagocytose monosodium urate crystals. The found be a glycoprotein mol wt 8,400 daltons. is heat labile has activity as well cells. Preincubation induced or complement activated plasma prevents cell migrating chemotactically when challenged either in chamber. induces release enzymes cytochalasin B treated neutrophils.
Pegloticase is a recombinant mammalian uricase conjugated to polyethylene glycol approved in the United States for treatment of chronic refractory gout. It can profoundly decrease serum urate < 1 mg/dl. In patients receiving pegloticase who did not generate high-titer antidrug antibodies (responders), remained low duration therapy, 6 months phase III clinical trials plus open-label extension. The objective this study was assess velocity tophus resolution subjects treated with pegloticase....